Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
5
×
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
5
×
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
boston top stories
novartis
cancer
clinical trials
gene therapy
ipo
vc
venture capital
cancer immunotherapy
celgene
crispr
deerfield management
What
bio
ipo
5
×
roundup
5
×
biogen
covid
medicines
new
week
years
acquisitions
activity
allogene
america
announced
approvals
arena’s
bounty
cancer
ceo
cig
clamped
collabs
comeback
companies
continues
convoluted
corner
crispr
daniel
deal
deals
delays
delivered
democrats
developing
diversity
dreams
economic
expressing
fast
Language
unset
Current search:
roundup
×
" raleigh-durham blog main "
×
" san francisco blog main "
×
ipo
×
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More